These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein. Kumar D; Gauthami S; Uma M; Nagalekshmi K; Rao PP; Basu A; Ella KM; Hegde NR Viral Immunol; 2018 Sep; 31(7):500-512. PubMed ID: 30095362 [TBL] [Abstract][Full Text] [Related]
17. Ebola virus vaccines - reality or fiction? Mire CE; Geisbert TW; Feldmann H; Marzi A Expert Rev Vaccines; 2016 Nov; 15(11):1421-1430. PubMed ID: 27078187 [TBL] [Abstract][Full Text] [Related]
18. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. Zhou Y; Sullivan NJ Curr Opin Immunol; 2015 Aug; 35():131-6. PubMed ID: 26247875 [TBL] [Abstract][Full Text] [Related]
19. [Potential vaccine candidates against Ebola and the first vaccine against chikungunya virus infection]. Nau JY Rev Med Suisse; 2014 Aug; 10(439):1570-1. PubMed ID: 25272676 [No Abstract] [Full Text] [Related]
20. Development of vaccines for prevention of Ebola virus infection. Ye L; Yang C Microbes Infect; 2015 Feb; 17(2):98-108. PubMed ID: 25526819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]